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ABSTRACT The pigment epithelium-derived factor (PEDF) is a glycoprotein with a molecular weight of 50 kDa be-
longing to the noninhibitory serpin family. It regulates several physiological processes, such as stimulation of retino-
blastoma cell differentiation into neuron cells, and facilitation of the growth and viability of photoreceptor cells and 
neurons of the central nervous system. Moreover, this factor protects neuronal cells against apoptosis. PEDF is not 
only a neurotrophic factor, but also a natural angiogenesis inhibitor. This protein, as well as its biologically active 
fragments, possesses significant neuroprotective, neurotrophic, and antiangiogenic capabilities. The precise molecular 
mechanisms underpinning the effects of PEDF are still not quite clear. However, this protein generates great interest 
as a promising drug for the therapy of a wide range of neurodegenerative, ophthalmological, and oncological diseases. 
This review is a summary of what is known today about the structural features, biochemical properties, and multimo-
dal functions of PEDF.
KEYWORDS PEDF (pigment epithelium-derived factor),  serpin,  neurotrophic factor,  angiogenesis.
INTRODUCTION 
PEDF (Pigment Epithelium-Derived Factor) was iden-
tified first in 1989 by a group of American researchers 
led by L.V. Johnson. It was purified from the growth 
medium of a culture of retinal pigment epithelium 
cells extracted from a human fetus [1, 2]. This growth 
medium was found to stop unlimited cell division and 
growth in Y-79 retinoblastoma cells. Moreover, 90% of 
the cells acquired the morphological and biochemical 
characteristics of mature neurons [1]. Electrophoretic 
and chromatographic means allowed to purify a 50 kDa 
protein from the growth medium, which was responsi-
ble for the observed effects on Y-79 cells. As was shown 
later, human PEDF consists of a single polypeptide 
chain that is 418 a.a. long (Fig. 1) [3].
Practically at the same time, PEDF was extracted 
from a culture of human lung fibroblast-like cells (WI-
38) [4]. The murine analog of PEDF, caspin, was also 
discovered [5]. Human PEDF and caspin cDNA are 
82.7% identical, whereas the amino acid sequences of 
the two are 85.6% identical. 
Current research shows that PEDF is expressed in 
almost all mammalian and avian tissues and has nu-
merous important functions. These include a differen-
tiating effect on embryo and tumor cells, a protective 
effect on mature neurons and other neural tissue cells, 
and antiangiogenesis activity – the ability to inhibit the 
formation of new blood vessels. This is why this protein 
is of major interest as a regulatory factor of cell and 
tissue growth. 
PEDF PRIMARY STRUCTURE AND ITS ENCODING GENE
The human PEDF gene and the encoded protein
The pedf gene is localized on the short arm of chromo-
some 17 in its distal region – 17p13.3 [6, 7]. It is approxi-
mately 15 kbp long and includes 8 exons interspersed 
with 7 introns. The exon-intron contacts are all in ac-
cordance with the GC/AG consensus. The length of the 
exons varies from 92 to 377 bp. The promoter region of 
the gene is located in the 5’-flanking region, and the 
CAAT-box is located in the -43 position from the tran-
scription initiation site. A cluster of Alu-repeats which 
includes 8 complete and 3 partial Alu-repeats is located 
in the 5’-terminal region of pedf, up to -5 kbp [8]. 
The pedf gene encodes a sequence of 418 a.a. [3]. The 
N-terminal region of PEDF, right after the initiatory 
methionine, includes a 17 a.a. stretch of hydrophobic 
amino acids, with a sequence characteristic of a signal-
ing fragment that targets the protein for secretion [3, 
9]. However, according to some reports, the sequence 
of mature PEDF secreted from producing cells begins 
with Asn21, and according to these data the polypep-
tide chain consists of 398 a.a. [10, 11]. Posttranslational 
modifications of blood serum PEDF include an N-ter-
minal residue of pyroglutamic acid, which is formed 
via deamination of the Gln2 residue, and the canonic 
N-glycosylation site Asn-Leu-Thr in positions 285-287. 
The added polysaccharides are heterogenic and have a 
molecular weight of approximately 4 kDa; their pres-
ence explains the difference between the calculated 
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and actual masses of the factor [12]. According to 2D 
electrophoresis data, human PEDF secreted by pig-
ment epithelium cells has 4 isoforms, whose isoelectric 
points are 6.0; 6.2; 6.4 and 6.6 [13]. 
PEDF is a member of the noninhibitory serpine family
Based on the analysis of the primary structure of the 
protein and corresponding cDNA, PEDF was included 
into the serpine family (serine proteases inhibitors) [14].   
Amino acid sequences of the factor and a1-antitrypsin 
are 27% identical (42% if equivalent substitutions are 
factored in), and 27 and 26% identical with a1-an -
tichemotrypsin and a2-plasmin inhibitor, respectively 
(44 and 43% if equivalent substitutions are factored in) 
(Fig.2) [3]. It is known that 51 a.a. residues are necessary 
to form a spatial structure of the serpine type [15], in 
PEDF there are 39 coincidences (76%) [16]. Despite the 
high level of similarity with the primary and spatial 
structures of serine protease inhibitors, PEDF does not 
inhibit these enzymes [17]. This may possibly be due to 
the structural characteristics of the exposed reactive 
loop of the factor. Even though it is equal in length to 
other serpines (17 a.a. residues Glu366-Leu382) [18,19], 
its content lacks some elements that are characteris-
tic of inhibitor serpines – Ala-rich sequences (in the 
9th and 12th loop positions) and Thr in positions 8 and 
14, while also possessing proline residues, which is not 
characteristic of serpines [16]. 
The structure of PEDF is similar to other serpines in 
that it possesses a bond that is especially prone to pro-
teolysis in a loop exposed into the cytoplasm [14], as do 
other serpines. Limited proteolysis of PEDF with vari-
ous serine proteases (chemotrypsin, elastase, subtilisin, 
etc.) reduces its molecular mass by approximately 4 
kDa. It has been determined that these proteases hy-
drolyze the Leu382-Thr383 bond, which results in the 
release of a 36-a.a. residue fragment from the C-ter-
minus. Unlike inhibitory serpines, no covalent bond is 
formed between the PEDF molecule and the active site 
of the proteinase. PEDF with a truncated C-terminus 
conserves its ability to differentiate Y-79 cells into ma-
ture neurons [20]. 
After the release of the 36-a.a. fragment, the general 
ellipticity of the molecule is reduced, indicating that the 
molecule experiences a reduction in the a-helix struc-
ture. Unlike inhibitory serpines, this process lowers 
the thermal stability of the PEDF molecule. However, 
these conformational alterations are not widespread 
and involve only the C-terminal region located near the 
exposed loop. The functional role of the latter and the 
Fig. 1. Amino acid sequence of the PEDF protein. The bond Leu382-Thr383 is marked in bold red. Yellow highlights mark 
the serpine loop, and light blue marks the N-glycosylation site. Green – peptide responsible for the antiangiogenic func-
tion; pink – peptide responsible for the neurotrophic function. Grey – phosphorylation sites. Blue – cluster of negatively 
charged amino acids, brown – positively charged amino acids. 
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Fig. 2. Comparison of the amino acid sequences of human 
PEDF and α1-antitrypsin (HUMA1AT). Colons (:) depict 
identical amino acids, and periods depict conserved sub-
stitutions [3]. 64 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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released C-terminal fragment of PEDF remain largely 
unstudied. Verified data demonstrate that the residues 
present in this region of the molecule, in conjunction 
with the N-terminal signaling peptide, are needed for 
the secretion of PEDF from the cell. 
Removal of the Pro415-Pro418 and Pro373-Ala380 
fragments, as well as point substitutions of Gly376, 
Leu377, Pro393, Phe394, or Phe396 (the first two are 
located in the exposed loop), either results in changes 
of the spatial structure of the molecule or alters its in-
teraction with other proteins, presumably transporters.   
PEDF transfer from the endoplasmic reticulum into the 
Golgi apparatus is disrupted, which prevents PEDF se-
cretion [16, 21]. 
Spatial structure of PEDF. Asymmetrical localization 
of positive and negative charges in the PEDF molecule
A mature molecule of the factor is a globule with a ra-
dius of <3.05 nm. Approximately 60% of PEDF amino 
acid residues are involved in the formation of 10 a-hel-
ices and 3 b-sheets [22]. Ser24, Ser114, and Ser227 are 
phosphorylation sites. The factor includes two impor-
tant amino acid sequences – a 34 a.a stretch (Asp34-
Asn77) and a 44 a.a. stretch (Val78-Thr121) – which are 
responsible for the antiangiogenic and neurothrophic 
interactions, respectively (Fig. 3) [23].
An interesting feature of the PEDF molecule is the 
presence of positively and negatively charged amino 
acid clusters, located on opposite sides of the globule. 
These clusters allow the factor to bind with structur-
al elements of the extracellular matrix, namely gly-
cosaminoglycans and collagen, via electrostatic bonds 
[24, 25].
The cluster of negatively charged residues (Asp and 
Glu) is located in two regions of the polypeptide chain, 
which are exposed on the surface of the globule, ad-
jacent to each other: Glu41-Asp64 (residues Glu41, 
Glu42, Glu43, Asp44, and Asp64) and Asp256-Glu304 
(residues Asp256, Asp258, Glu290, Glu291, Glu296, 
Asp300, and Glu304). The presence of this cluster 
determines PEDF affinity to type I, II, and III colla-
gens [25]. PEDF binding to collagens, as well as to gly-
cosaminoglycans, is weakened in high ionic strength 
solutions, since the bonds are electrostatic in their na-
ture. The peptide fragments Val40-Arg67 and Phe277-
Ile301, which are also involved in the formation of this 
cluster, are conserved from fish to mammals [16]. 
The cluster of positively charged amino acids, which 
includes 12 residues of Arg, Lys, and His, is located in 
the Lys 134-Lys214 region. Residues Lys134, Lys137, 
Lys189, Lys191, His212, and Lys214 form the “core” 
of the cluster, while residues Arg141, Lys146, Lys147, 
Arg149, Arg165, and Arg167 are located on the pe-
riphery. This local positive charge allows the binding 
of PEDF to polyanionic molecules which are rich in 
charged sulfate groups, such as heparin, chondroitin 
sulfate, etc. This cluster is also involved in the interac-
tion between PEDF and the glycosaminoglycans in the 
interphotoreceptor matrix of the retina [24]. 
Apart from the cytoplasm, PEDF can also be found 
inside the nucleus. It seems that the positively charged 
Lys146-Arg149 fragment can act as a nuclear locali-
zation sequence. Notably, only 10 of the studied 6,000 
proteins, including PEDF, possess a C-terminal glyco-
sylation site; all of these proteins are localized in the 
nucleus [16]. In its role as a nuclear protein, PEDF may 
possibly be involved in cell cycle regulation. 
Charges on the surface of the PEDF molecule are 
positioned in an asymmetric fashion – the clusters of 
basic and acidic amino acids are on opposite sides of the 
globule. This allows PEDF to simultaneously interact 
with glycosaminoglycans and collagen. Interaction with 
glycosaminoglycans increases PEDF affinity towards 
collagen and vice versa [25]. Thus, PEDF can modulate 
cell adhesion processes that involve integrin-collagen 
interactions. Since cell adhesion is one of the key stages 
of angiogenesis, this may indeed be the basis for the 
antiangiogenic activity of the factor [25]. 
Fig. 3. 3D crystal structure of PEDF. This figure shows two 
projections on the vertical axis with a shift of 90°. The pep-
tide responsible for the antiangiogenic function is marked 
in green, and the one responsible for the neurotrophic 
function is marked in orange. Red marks the negatively 
charged amino acids which form the collagen-binding clus-
ter, and purple marks the positively charged amino acids 
which form the “core” of the glycosaminoglycan-binding 
cluster. Phosphorylation sites (Ser114 and Ser227) are 
marked in yellow, and the glycosylation site at Asn285 
with the bound sugar residues is marked in light blue [23]. REVIEWS
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Phosphorylation of PEDF influences its antiangiogen-
ic and neurotrophic activity 
PEDF purified from human plasma is a phosphopro-
tein. There are three phosphorylation sites on the sur-
face of the PEDF molecule - Ser24, Ser114, and Ser227. 
PEDF possesses and other potential phosphorylation 
sites; however, in normally folded molecules these sites 
are unavailable for kinases. In the seum  factor  is phos-
phorylated mainly by casein kinase 2 on 2 main resi-
dues, Ser24 and Ser114, but also by protein kinase A on 
Ser227  [26]. PEDF is functionally modulated by extra-
cellular phosphorylation. The casein kinase 2 phosphor-
ylated PEDF has a reduced neurotrophic activity, while 
its antiangiogenic activity is significantly increased. On 
the other hand, protein kinase A phosphorylation re-
duces the PEDF antiangiogenic activity but has only a 
slight effect on its neurotrophic activity.  A fully phos-
phorylated factor displays both high antiangiogenic 
and neurotrophic activities.
Casein kinase 2 phosphorylation of  Ser24 and Ser114   
prevents further phosphorylation of PEDF by protein 
kinase A, and partial denaturation of protein restores 
its sensitivity to protein kinase A phosphorylation.  Ca-
sein kinase 2 phosphorylation is followed by a confor-
mational change in the PEDF molecule, thereby making 
Ser227 inaccessible to protein kinase A phosphoryla-
tion. On the other hand,  protein kinase A phosphoryla-
tion  of PEDF does not affect the conformational state 
of the casein kinase 2 phosphorylation sites and allows 
their further phosphorylation. The inhibitory effect of 
the casein kinase 2 phosphorylated PEDF on its protein 
kinase A phosphorylation may serve as a regulatory 
mechanism of PEDF function under conditions where 
the highly antiangiogenic activity of PEDF should be 
preserved while its neurotrophic activity should be 
eliminated. On the other hand, the protein kinase A 
phosphorylation of PEDF reduces PEDF antiangiogenic 
function. PEDf could be further phosphorylated by ca-
sein kinase 2, and that converts it from a poor to a very 
potent antiangiogenic factor that maintains its neuro-
trophic activity [27]. This is a novel role of extracellular 
phosphorylation that completely changes the nature of 
the physiologic activity of a circulating protein. Thus, 
differential phosphorylation induces variable effects 
of PEDF and therefore contributes to the complexity 
of PEDF action. 
Occurrence and evolutional conservation of PEDF
The pedf gene is conserved and can be found in the ge-
nomes of various animal species, ranging from fish to 
humans (Fig. 4, 5) [16]. Through DNA-RNA hybridi-
zation methods, researchers discovered that PEDF 
mRNAs were present in nearly all 44 of the examined 
tissues of adult humans and human embryos. It is pre-
sumed that PEDF is expressed mainly by cells that 
have not lost their ability to divide in vivo [28]. In vari-
ous regions of the eye and layers of the retina in human 
adults and embryos, antibodies to the PEDF polypep-
tide interacted with the cytoplasm of developing pho-
toreceptors, the glial layer, single cells in the neuroblast 
layer, and pigment granules in pigment epithelium cells 
(starting from the 8th week of embryo development). In 
the organism of an adult, the antibodies interacted with 
the nuclei of rods (but not with those  of cones), with 
the cytoplasm of certain cells in the nuclear and glial 
layers, with pigment epithelium cells, choriocapillaris 
of the cornea, the pupil, and ciliated epithelium [29]. 
The most conserved species-specific peptide frag-
ments are the following sequences [16]. The leading 
N-terminal region of the factor responsible for the se-
cretion of PEDF from the cell was conserved during 
the course of evolution [30]. Another highly conserved 
sequence, Asn285-X-Thr287, is an N-glycosylation 
site. Four other peptide fragments are also conserved:   
two of which are unique to PEDF and form a cluster 
of negatively charged amino acids, and two others (in 
positions Val78-Gly95 and Phe384-Pro415) which are 
similar to other serpines. It seems that the functions of 
the latter two are similar for all serpines. 
EFFECTS OF PEDF ON CELLS AND 
TISSUES OF VARIOUS ORIGINS
Differentiation effect of PEDF and its effect on me-
tabolism
The differentiation  effect of the neurotrophic PEDF 
factor was shown and studied on neuronal cells  – both 
on embryonic (immature neurons, developing photore-
ceptors) [31,32] and tumor cells (neuroblastoma, retino-
blastoma, and carcinoma) [3,33,34]. Human and bovine 
PEDF has a differentiation effect on in vitro cell cul-
tures of immature motor neurons obtained from chick-
en embryo (5.5 days old) spinal cords [35]. PEDF is the 
main factor that controls normal morphogenesis and   
metabolism of photoreceptor and glial cells during the 
embryonic development of the retina [32, 36, 37]. 
PEDF has differentiation and antiproliferative ef-
fects on Y-79 retinoblastoma cells [1, 3]. The antitumour 
effect can also be observed on neuroblastoma cells. For 
this type of tumour, clinical prognosis  is usually bet-
ter when the population of cells is rich in differentiated 
neurons and Schwann cells, whose cultural  medium 
has antitumor properties [38]. PEDF, which is one of 
the secreted products of Schwann cells, mediates the 
antitumor effects observed for these cultural  media 
[33]. 
PEDF also has an antitumor effect on ovarian epi-
thelial carcinoma, which is the most lethal type of  can-66 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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Fig. 4. Compari-
son of the amino 
acid sequences of 
PEDF proteins of 
different origins. 
14 sequences of 
the factor from 
different biological 
species (human, 
Homo sapiens; 
chimpanzee, Pan 
troglodytes; 
domestic cow, 
Bos taurus; pig, 
Sus scrofa; dog, 
Canis canis; 
mouse, Mus mus-
culus; rat, Rattus 
norvegicus; 
chicken, Gallus 
gallus; Western 
clawed frog, 
Xenopus tropica-
lis; African clawed 
frog, Xenopus 
laevis; Japanese 
ricefish, Oryzias 
latipes; fugu, Tak-
ifugu rubripes; 
rainbow trout, 
Oncorhynchus 
mykiss; zebra fish, 
Danio rerio) were 
analyzed using 
ClustalW soft-
ware. Asterisks 
mark the positions 
of fully conserved 
residues. Colons 
indicate that a 
“strong” func-
tional group is 
conserved; peri-
ods indicate that 
a “weak” group 
is conserved. The 
blue line marks 
the PEDF leader 
sequence. The 
double red line 
marks regions that 
are highly con-
served in all the 
PEDF sequences. 
Dashes are used 
for the maximal 
alignment of the 
sequences [16]. REVIEWS
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cers. The level of PEDF expression in ovarian tumors 
and their cell lines is significantly lower in comparison 
with normal ovarian epithelium. Exogenous PEDF in-
hibits the growth of both normal and tumour  ovarian 
epithelium, while a decreased activity of endogenous 
PEDF accomplished through the injection of inhibitors 
results in increased proliferation  of these cells. 
The effect of PEDF on ovarian epithelial cells is 
mainly regulated by estrogens. Treatment of cell lines 
with 17β-estradiol lowers the production of PEDF and 
its mRNA by repressing the transcription of the pedf 
gene. Estrogen receptors play a role in this regulation. 
17β-estradiol promotes the growth of normal and can-
cerous tumour  ovarian epithelium cell lines, while si-
multaneous treatment with 17β-estradiol and PEDF 
negates the stimulating effect [34]. Some lines of ovarian 
carcinoma bear a deletion in the 17 chromosome at locus 
17p13.3. This deletion is 15 kbp long and includes most of 
the pedf gene [39]. Proliferation of these cell lines cannot 
be stimulated by 17β-estradiol, which seemingly indi-
cates that its effector region in the 5’-flanking region 
of pedf is also deleted. Epigenetic modifications, such as 
hypermethylation of the promoter, may act as alterna-
tive mechanisms for regulating pedf expression [34]. 
In pigment epithelium cells, PEDF stimulates the 
synthesis and accumulation of melanin [40].  The impor-
tance of melanin in the development of retinal neurons 
is suggested by the fact that, irrespective of the causa-
tive factors for albinism, all mammal albinos display 
impaired visual signals [41]. The factor boosts the activ-
ity of the promoter of the tyrosine kinase gene, whose 
product is involved in the synthesis of melanin [42]. 
Neuroprotective effect of PEDF
PEDF was shown to prevent apoptosis of cells in a cul-
ture of retinal neurons after H2O2 treatment [43]. Pre-
treatment with PEDF protects the pigment epithelium 
from the disruptions in the barrier function caused by 
H2O2. It also protects the cells from other effects of hy-
drogen peroxide: redistribution of the synaptic proteins 
occludin and N-cadherin in cell membranes of the pig-
ment epithelium; reorganizations of actin and activa-
tion of the signaling cascade mediated by the p38/27 
kDa heat chock protein [44].  
The factor also has a protective effect on cultures of 
primary cerebellum granular cells extracted from baby 
rats (8 days old). It considerably slows spontaneous and 
serum deprivation-mediated apoptosis in this culture 
[45, 46]. PEDF also protects cerebellum granular cells 
[47], hippocampus neurons [48], and spinal motor neu-
rons [49] from the toxic effects of glutamate. According 
to certain data, the main mechanism responsible for 
the protective effect of PEDF on granular cells is the 
activation of the NF-κB transcription factor [50]. 
Antiangiogenic effect of PEDF
PEDF is one of the most potent antiangiogenic factors. 
It inhibited vessel growth in rat corneas that were stim-
Fig. 5. Interspecies 
identity of the ami-
no acid sequences 
of PEDF in percent-
age points. The 
table was gener-
ated using PSI-Blast 
software [16]. 68 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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ulated with bFGF, which is a very potent angiogenic 
factor. The effective concentration of PEDF is much 
lower than that of the most potent, previously known 
antiangiogenic factors – angiostatin, endostatin, and 
thrombospondin [51]. The factor is involved in the com-
plex and balanced control of angiogenesis, acting in op-
position to angiogenic factors such as VEGF ((vascular 
endothelial growth factor) and bFGF (basic fibroblast 
growth factor) [52–55]. 
Saturation of tissues with oxygen affects the concen-
tration of PEDF. Hyperoxygenation causes the forma-
tion of retinas with decreased amounts of blood vessels, 
while (though) the level of PEDF expression in these 
conditions was shown to be high [56]. Hyperoxygena-
tion stimulates factor production; hypoxia, on the other 
hand, has a repressive effect.
The mechanism responsible for the antiangiogenic 
effect of PEDF is currently under study. Endothelium 
cells display positive chemotaxis towards angiogenic 
factors. Thus, one of the mechanisms of PEDF action 
is the inhibition of the chemotaxis of endothelial cells, 
which form the walls of blood vessels. This effect in-
hibits chemotaxis towards all of the studied angiogenic 
factors – VEGF, PDGF, IL-8, etc. [51].
According to other data, the reason for the antian-
giogenic effect of PEDF is the apoptosis of endothelial 
cells [57]. A characteristic trait of the factor is its selec-
tive effect on growing vessels; it does not damage any 
functioning vessels [58]. The reason for such a selective 
effect is the mode of apoptosis induction, mediated by 
the Fas-ligand [59]. Angiogenic agents stimulate en-
dothelial cells towards producing a range of anti-ap-
optotic molecules, which increase their viability [60], 
and they also stimulate Fas-receptors. Vessels that are 
already functioning have their endothelium cells in a 
state of “arrested growth,” with the cells in tight con-
tact with each other.  Fas-receptor expression is also 
decreased [61]. These factors protect cells from the ap-
optotic effect of PEDF. 
Nonetheless, besides PEDF having a stimulating ef-
fect on Fas/FasL expression and Fas-mediated apop-
tosis, there must be alternative pathways for the apop-
totic activity of the factor, since Fas and FasL knockout 
mice are still sensitive to PEDF-mediated apoptosis [57, 
62, 63]. It has been shown that PEDF can activate p38 
MAPK in a culture of epithelial cells extracted from 
a human umbilical vein (HUVEC) by promoting their 
phosphorylation. Activation of p38 results in the activa-
tion of caspases 3, 8, 9 and, ultimately, in cell apoptosis 
[64]. 
It is notable that VEGF also promotes p38 phospho-
rylation, and this effect is potentiated during co-treat-
ment with PEDF. One of the most important functions 
of VEGF is to protect endothelial cells from apoptosis 
in various conditions, including medium depletion. Ac-
tivation of the p38 kinase by VEGF is accomplished by 
regulation of its transcription [65, 66] and cytoskeleton 
reorganization, as well as cell migration [67]. It seems 
likely that the threshold concentration of phosphor-
ylated p38 MAPK needed for the proangiogenic effect 
to manifest is lower than the concentration needed for 
the activation of the apoptosis pathway. The PEDF-
mediated increase in the level of activated p38 can re-
sult in concentrations of p38 that exceed the threshold 
concentration and, thus, cause apoptosis [64].
Even though PEDF stimulates the apoptosis of en-
dothelial cells, it prevents the apoptosis of various cells 
of neural origin. PEDF can have the opposite effects on 
endothelial cells of differing phenotypes [68]. In these 
cases, it is possible that the factor’s action is effected 
via different unrelated mechanisms. 
PEDF RECEPTOR
The multiple functions of PEDF are obviously realized 
through different mechanisms. However, it seems like-
ly that in most cases the interaction between PEDF and 
cells takes place via a ligand-receptor mechanism. The 
effects of the factor can be blocked by antibodies which 
prevent the factor from binding to the cell’s surface 
[47,69,70]. 
Not long ago, researchers managed to identify a gene 
whose product acted as a PEDF receptor. The gene was 
thus named PEDF-R. This discovery was made using 
a two-hybrid system in retinal cells [72]. The gene is 
localized in region 11p15.5 in chromosome 11 and con-
sists of 10 exons and 9 introns. The mRNA transcript 
of pedf-r is 2122 bases long. It encodes a protein mol-
ecule which consists of 504 amino acids (molecular mass 
of 55.315 kDa). The sequence contains 4 consensus N-
glycosylation sites. When expressed in eukaryotic sys-
tems, the receptor has a mass of approximately 81 kDa, 
which is similar to the mass of PEDF-binding proteins 
on the cell’s surface. The latter were identified previ-
ously in cell lines of human retinoblastoma (Y-79), in 
rat cerebellum granular neurons, and in cells extracted 
from bovine retinas [70,71]. 
The receptor is mainly produced in retinal pigment 
epithelium cells, the inner segments of photoreceptors, 
and neuronal cells of the retina. However, the recep-
tor is not detected in the outer segments of rods. Apart 
from normal pigment epithelium cells, PEDF-R is also 
present in a number of other tissues and organs – in the 
optical nerve, uvea, retinoblastoma cells, other tumors 
of various origins, as well as animal brain cells that 
were in a state of serotonin and catecholamine deple-
tion. The gene encoding this receptor has been evolu-
tionarily conserved in mammals. The highest degree 
of similarity was observed between human PEDF-R REVIEWS
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and that of mice (89% identical) and rats (89% identical). 
Genes homologous to PEDF-R have also been found in 
the genomes of nematodes (Caenorhabditis elegans) and 
mosquitoes (Anopheles gambiae). 
PEDF-R is a transmembrane protein with four 
transmembrane, two extracellular and three intracel-
lular domains; the N- and C-termini of the molecule are 
exposed into the intracellular environment (Fig. 6) [72]. 
PEDF-R can bind PEDF with a Kd ~ 3.03 ± 0.716 nM 
both in solution, as well as after immobilization of one of 
the proteins. It retains this ability even after denatur-
ation and refolding. Posttranslational modifications, in-
cluding N-glycosylation, are not required for the factor 
to bind to the receptor – PEDF-R expressed in bacteria 
interacts with PEDF with a Kd nearly identical to that 
observed under normal conditions. The factor-bind-
ing domain of PEDF-R has been identified as Gln250-
Arg383 and is called 12c. This fragment was shown to 
be highly similar to type I rat collagen. It seems likely, 
however, that this is not the only fragment that plays a 
role in PEDF binding, since the factor’s affinity towards 
a full-sized receptor is higher. The dissociation constant 
of the latter is nearly two orders of magnitude larger 
than that of the 12c fragment ((Kd.12с ~ 134 nM).
The factor-receptor interaction involves the Val78-
Thr121 fragment of the PEDF molecule. A synthetic 
analog (44-a. a. residues long) retains the ability to bind 
to the receptor [70]. 
Apart from the ability to bind PEDF, PEDF-R also 
manifests phospholipase activity and has been classified 
as a member of the calcium-independent, A2 phospholi-
pase family. Another feature of the PEDF-R sequence 
is two spatially adjacent patatin-like fragments (Asn39-
Ala54 and Ser158-Tyr177) that form a Ser47/Asp166 
catalytic dyad, which is present in the active sites of 
patatin B2 and human cytosolic A2 phospholipases [73]. 
A2 Phospholipases release lysophospholipids, which 
play a role in cell signaling and affect the development 
and functioning of all mammalian organ systems [74]. 
A2 phospholipases also release biologically active fatty 
acids from the cell’s membrane. These acids act as mes-
sengers or as precursors of eicosanoids, which mediate 
signal transduction [75]. Arachidonic and docosahex-
aenoic acids, which are abundant in the membranes of 
cells in the retina and the central nervous system, can 
influence the viability of retinal and central nervous 
system cells [76, 77] and demonstrate antitumor and 
antiangiogenic effects, similar to PEDF [78,79]. 
PEDF-R can hydrolyze arachidoinoyl-sn-glycerin-
3-phosphocholine, thus releasing arachidonic acid [80].   
Even though there is currently no data on the release 
of docosahexaenoic acid by PEDF-R, it has been shown 
that PEDF in subnanomolar concentrations can acti-
vate the synthesis and release of its derivatives from the 
ARPE-19 human cell line [81, 82]. These data indicate 
that PEDF can facilitate the survival of retinal cells by 
influencing the lipid signaling pathways that are con-
nected with PEDF-R. Interaction of PEDF with its re-
ceptor, PEDF-R, results in the release of fatty acids and 
lysophospholipids from cell membranes. These entities 
act both para- and autocrinally, by raising the viabil-
ity and differentiation potential of neuronal cells, or by 
causing the death of tumor and endothelial cells [72].
PEDF AS A SUBSTRATE OF MMP-2 AND MMP-9
As previously mentioned, regulation of angiogenesis 
is very dependent on the quantitative ratio between 
the differentiation factors VEGF and PEDF. It has 
been shown that increasing the concentrations of ex-
ogenous PEDF in a model of choroidal neovasculariza-
tion stimulates the production of VEGF by endothelial 
cells. In turn, increased concentrations of VEGF induce 
the production of matrix metalloproteases MMP-2 and 
-9 (or the corresponding gelatinases A and B). The ac-
tivated proteinases hydrolyze the components of the 
extracellular matrix and the PEDF previously bound 
to these components. However, they do not influence 
VEGF. Thus, increased concentrations of PEDF result 
in elevated inactivation of this factor by MMP, which 
increases the VEGF/PEDF ratio and stimulates ang-
iogenesis. 
The region of PEDF most accessible for proteolysis 
by MMP-2 and -9 is the exposed loop that contains the 
Leu382-Thr383 bond. However, apart from this bond, 
the PEDF sequence also has several sites for MMP-2 
and -9 proteolysis, which are partially or completely 
“masked” by a tertiary structure. These sites are less 
accessible to the activity of matrix metalloproteinases. 
It is possible that the activity of MMP-2 and/or -9 re-
sults in a gradual loss of its tertiary structure by the 
PEDF molecule, making the inner bonds more accessi-
ble to metalloproteinases. Complete proteolysis creates 
N1
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Fig. 6. Topology of PEDF-R predicted according to its 
amino acid sequence. The thick lines indicate the trans-
membrane domains [72].70 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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a multitude of peptide fragments, which manifest no 
antiangiogenic or neurotrophic activity even though 
they retain the ability to bind components of the extra-
cellular matrix. Thus, matrix metalloproteinases can 
inactivate PEDF through the same mechanism as the 
one effected by inhibitory serpines (such as antitrypsin 
and antithrombin III). They affect the reactive site of 
the loop and are thought to form a stable inactive com-
plex with the factor molecule (although the existence of 
such a complex has yet to be proven). However, there is 
still a possibility that the loss of biological activities by 
PEDF is achieved by the complete gradual proteolysis 
of the protein [83]. 
CONCLUSION
The PEDF protein has been the subject of intensive 
studies for several years, and the amount of PEDF-
related research increases with every year. It has 
been shown that the protein regulates a wide range of 
processes in the cells and tissues of various eukaryo-
tic organisms, including in those of humans. PEDF is 
a key player in high-level intracellular interactions, 
though it is possible that some of its functions in the 
metabolic pathways of the cell have yet to be identi-
fied. The antiproliferative, antiangiogenic, protective, 
differentiative and other activities of PEDF are very 
promising not only from the viewpoint of basic scien-
tific research, but also for the use of this protein in the 
treatment of various diseases, such as neurodegenera-
tive damage to the optical and nervous systems and 
cancerous processes. 
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